Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 5/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17827708 | 0.88 | MEN1 (0.40) | CHKAHRH1MEN1KMT2AHRH2 | |
| SCHEMBL17827674 | 0.82 | HRH1 (0.49) | CHKAHRH1MEN1KMT2AHRH2 | |
| SCHEMBL17827662 | 0.81 | HRH2 (0.52) | HRH1HRH2HRH3GAAMAPT | |
| SCHEMBL17827670 | 0.79 | METAP1 (0.43) | CHKAHRH1HRH2HRH3CA12 | |
| SCHEMBL17827679 | 0.77 | CHKA (0.47) | CHKAHRH1HRH2HRH3CA12 | |
| SCHEMBL16439231 | 0.75 | CHKA (0.48) | CHKAHRH1HRH2HRH3AKR1C3 | |
| SCHEMBL17827666 | 0.74 | MAPT (0.47) | CHKAHRH1HRH2HRH3CA12 | |
| SCHEMBL17827700 | 0.74 | CHKA (0.53) | CHKAMAPT | |
| SCHEMBL17827690 | 0.73 | CHRM1 (0.49) | CHKA | |
| SCHEMBL17827685 | 0.73 | RIPK3 (0.42) | CHKAHRH1HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-12 | — | — | US | disclosed |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, PIR | CHKA 4208/4885HRH1 258/4885MEN1 4843/4885 |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, PIR | CHKA 4208/4885HRH1 258/4885MEN1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.